Teclistamab Dosing and Adverse Event Prophylaxis Practices
Following a review of recent data from MajesTEC-1 investigating teclistamab, the panel provides clinical insights on dosing and adverse event prophylaxis practices.
Video content above is prompted by the following question(s):
- What factors could contribute to the observed decrease in the onset of new grade ≥3 infections over time, and what are the clinical implications?
Recent Videos
Related Content
The Hidden Danger Unveiling the Connection Between Multiple Myeloma and Pleural Effusion
FNU Fatima, MBBS;Faryal Arif, MBBS;Muhammad Hamza Gul, MBBS, MD;Neha Siddiqui, MBBS;Muhammad Zulqarnain, MBBS;Abdul Baseer Wardak, MBBS
November 8th 2024Article
This case highlights the importance of early recognition and management of pleural effusion in patients with multiple myeloma and underscores the need for further research into optimal management strategies and underlying mechanisms.
